TWI863239B - Gip/glp1共促效劑化合物 - Google Patents

Gip/glp1共促效劑化合物 Download PDF

Info

Publication number
TWI863239B
TWI863239B TW112115808A TW112115808A TWI863239B TW I863239 B TWI863239 B TW I863239B TW 112115808 A TW112115808 A TW 112115808A TW 112115808 A TW112115808 A TW 112115808A TW I863239 B TWI863239 B TW I863239B
Authority
TW
Taiwan
Prior art keywords
ethoxy
aib
glu
amino
acetyl
Prior art date
Application number
TW112115808A
Other languages
English (en)
Chinese (zh)
Other versions
TW202332688A (zh
Inventor
米拉塔 馬莉 亞伯拉罕
艾克森 阿布魯布
佛南德茲 喬治 亞利西納
羅伯 安德魯 布朗
歐佛 卡布雷拉
塔莫 寇斯康
羅伯 查威克 卡明斯
曼楠 亞迷塔 達塔
穆罕默德 艾沙耶德 哈米德 艾沙耶德
顯英 賴
菲尼爾 賈揚提拉勒 佩托
屈红昌
凱爾 温 史盧波
氏 青 玄 陳
詹姆士 林肯 沃利斯
法蘭西斯 斯塔福德 威拉德
Original Assignee
美商美國禮來大藥廠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商美國禮來大藥廠 filed Critical 美商美國禮來大藥廠
Publication of TW202332688A publication Critical patent/TW202332688A/zh
Application granted granted Critical
Publication of TWI863239B publication Critical patent/TWI863239B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/56—Protease inhibitors from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
TW112115808A 2018-07-23 2019-07-22 Gip/glp1共促效劑化合物 TWI863239B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862702072P 2018-07-23 2018-07-23
US62/702,072 2018-07-23
US201862730563P 2018-09-13 2018-09-13
US62/730,563 2018-09-13
US201862740596P 2018-10-03 2018-10-03
US62/740,596 2018-10-03

Publications (2)

Publication Number Publication Date
TW202332688A TW202332688A (zh) 2023-08-16
TWI863239B true TWI863239B (zh) 2024-11-21

Family

ID=67620523

Family Applications (3)

Application Number Title Priority Date Filing Date
TW112115808A TWI863239B (zh) 2018-07-23 2019-07-22 Gip/glp1共促效劑化合物
TW108125887A TWI735917B (zh) 2018-07-23 2019-07-22 Gip/glp1共促效劑化合物
TW110125507A TWI810606B (zh) 2018-07-23 2019-07-22 Gip/glp1共促效劑化合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW108125887A TWI735917B (zh) 2018-07-23 2019-07-22 Gip/glp1共促效劑化合物
TW110125507A TWI810606B (zh) 2018-07-23 2019-07-22 Gip/glp1共促效劑化合物

Country Status (27)

Country Link
US (3) US11084861B2 (https=)
EP (2) EP4549454A3 (https=)
JP (3) JP6920559B2 (https=)
KR (3) KR20240051304A (https=)
CN (2) CN119504975A (https=)
AU (2) AU2019311000B2 (https=)
BR (1) BR112020026671A2 (https=)
CA (3) CA3107345C (https=)
CL (1) CL2021000158A1 (https=)
CO (1) CO2021000453A2 (https=)
CR (1) CR20210040A (https=)
DO (1) DOP2021000016A (https=)
EC (1) ECSP21004913A (https=)
FI (1) FI3827015T3 (https=)
IL (1) IL279827A (https=)
JO (2) JOP20210016A1 (https=)
MA (1) MA53382A (https=)
MX (1) MX2021000793A (https=)
MY (1) MY197569A (https=)
PE (2) PE20260005A1 (https=)
PH (1) PH12021550154A1 (https=)
SA (1) SA521421080B1 (https=)
SG (1) SG11202100128UA (https=)
TW (3) TWI863239B (https=)
UA (1) UA129537C2 (https=)
WO (1) WO2020023386A1 (https=)
ZA (3) ZA202100235B (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
CN119499352A (zh) * 2018-07-23 2025-02-25 伊莱利利公司 使用gip/glp1共激动剂用于糖尿病的方法
KR20240051304A (ko) * 2018-07-23 2024-04-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
KR102812908B1 (ko) 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
MX2022006861A (es) 2019-12-04 2022-07-11 Scripps Research Inst Agonistas del receptor glp2 y metodos de uso.
IL294955A (en) * 2020-01-23 2022-09-01 Lilly Co Eli Cobalt-agonist gip/glp1 compounds
EP4110800A1 (en) 2020-03-06 2023-01-04 Sanofi Peptides as selective gip receptor agonists
WO2021198229A1 (en) 2020-03-31 2021-10-07 Antaros Medical Ab Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes
TW202216746A (zh) 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑
US20230346961A1 (en) 2020-07-22 2023-11-02 Novo Nordisk A/S Glp-1 and gip receptor co-agonists
EP4185607A1 (en) 2020-07-22 2023-05-31 Novo Nordisk A/S Co-agonists at glp-1 and gip receptors suitable for oral delivery
PE20231309A1 (es) 2020-10-17 2023-08-24 Sun Pharmaceutical Ind Ltd Agonistas duales glp-1/gip
AR124295A1 (es) 2020-12-18 2023-03-15 Lilly Co Eli Agonistas duales del receptor de amilina y calcitonina y usos de los mismos
CA3200209A1 (en) * 2020-12-22 2022-06-30 Eli Lilly And Company Therapeutic peptide formulations
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN117320740A (zh) * 2021-02-17 2023-12-29 伊莱利利公司 Gip/glp1双重激动剂治疗方法
TWI837615B (zh) * 2021-03-23 2024-04-01 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
US12215133B2 (en) 2021-03-25 2025-02-04 Brightgene Bio-Medical Technology Co., Ltd. GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use
WO2022199629A1 (zh) * 2021-03-25 2022-09-29 博瑞生物医药（苏州）股份有限公司 Gip和glp-1的双受体激动剂、药物组合物及用途
CN115181173A (zh) * 2021-04-02 2022-10-14 深圳市健元医药科技有限公司 一种Tirzepatide的制备方法
AU2022269659B2 (en) * 2021-05-07 2025-04-10 Eli Lilly And Company Erodible tablet
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
IL306122B2 (en) * 2021-05-28 2026-01-01 Guangdong Raynovent Biotech Co Ltd Preparation and use of polypeptide
EP4345105A4 (en) * 2021-06-01 2025-04-23 Nanjing Zhihe Medicine Technology Co., Ltd Polypeptide derivative with dual targeted activation of GLP-1R and GIPR, manufacturing process therefor and use thereof
KR20240032010A (ko) 2021-06-09 2024-03-08 더 스크립스 리서치 인스티튜트 장기 지속형 이중 gip/glp-1 펩타이드 접합체 및 사용 방법
CN115594752A (zh) * 2021-07-07 2023-01-13 成都奥达生物科技有限公司（Cn） 一种长效双激动剂化合物
KR20240055069A (ko) 2021-09-06 2024-04-26 사노피 효력있는 선택적 gip 수용체 작용제로서의 신규 펩티드
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
AU2022392980B2 (en) * 2021-11-19 2025-12-18 Jiangsu Deyuan Pharmaceutical Co., Ltd. Stapled peptide and use thereof
CN118234742A (zh) * 2021-12-01 2024-06-21 江苏恒瑞医药股份有限公司 Glp-1和gip受体双重激动剂的药物组合物及其用途
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
US20260055142A1 (en) * 2022-04-07 2026-02-26 Guangdong Raynovent Biotech Co., Ltd. Pharmaceutical use of polypeptide in preparation of drugs for treating and/or preventing diabetes and obesity and related diseases thereof
CN119907661A (zh) * 2022-07-05 2025-04-29 G2G生物公司 含有司美格鲁肽或其药学上可接受的盐的缓释微球制剂及其制备方法
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
JP2025530743A (ja) 2022-08-29 2025-09-17 イーライ リリー アンド カンパニー 経口投与のための組成物
CN119894921A (zh) * 2022-09-15 2025-04-25 伊莱利利公司 Gip和glp-1双重激动剂化合物
KR20250110330A (ko) * 2022-11-21 2025-07-18 일라이 릴리 앤드 캄파니 Gip/glp1 이중 효능제의 제조 방법
US20240270821A1 (en) 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
CN121464152A (zh) * 2023-06-30 2026-02-03 株式会社汇恩斯拉布 以glp类似物为有效成分的用于预防或治疗肥胖的药物组合物
WO2025087353A1 (zh) * 2023-10-26 2025-05-01 齐鲁制药有限公司 具有多重激动活性的多肽及其应用
TW202529796A (zh) * 2023-11-22 2025-08-01 大陸商杭州中美華東製藥有限公司 Glp-1r/gipr雙標靶激動劑在製備動物藥的用途
TW202540155A (zh) 2023-11-30 2025-10-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1、gip及澱粉素受體之三重促效劑
CN117624333A (zh) * 2023-12-05 2024-03-01 江苏师范大学 一类GLP-1受体、glucagon受体和GIP受体三激动多肽化合物及其应用
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
TW202542174A (zh) * 2023-12-29 2025-11-01 大陸商杭州中美華東製藥有限公司 Glp-1/gip雙激動劑的固相合成方法
WO2025147633A2 (en) * 2024-01-05 2025-07-10 Indiana University Research And Technology Corporation Gip/glp-1 co-agonists and their associated prodrugs
TW202535912A (zh) * 2024-01-12 2025-09-16 大陸商杭州中美華東製藥有限公司 長效glp-1/gip雙激動劑的鼻腔遞送藥物組合物
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025161155A1 (zh) * 2024-02-04 2025-08-07 内蒙古博睿精创科技有限公司 一种长效glp-1多肽化合物、组合物及其应用
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
WO2025264785A1 (en) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2025264809A1 (en) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2025264776A1 (en) * 2024-06-21 2025-12-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
JP2026031900A (ja) * 2024-07-24 2026-02-25 イーライ リリー アンド カンパニー Ｆｃ－アシル化ポリペプチドコンジュゲート

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201636362A (zh) * 2015-01-09 2016-10-16 美國禮來大藥廠 Ｇｉｐ及ｇｌｐ－１共促效劑化合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2694095T3 (en) * 2011-04-05 2018-05-28 Longevity Biotech Inc COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
IN2014MN02304A (https=) * 2012-05-03 2015-08-07 Zealand Pharma As
PE20150863A1 (es) * 2012-06-21 2015-06-11 Univ Indiana Res & Tech Corp Analogos de glucagon que exhiben actividad de receptor de gip
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
JP2016521253A (ja) 2013-03-15 2016-07-21 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション 持続性作用を有するプロドラッグ
KR102272671B1 (ko) 2013-05-02 2021-07-06 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
WO2015067715A2 (en) 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN108271356A (zh) * 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
WO2016198604A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as dual glp-1 /glucagon receptor agonists
US20170112897A1 (en) * 2015-10-23 2017-04-27 Cedars-Sinai Medical Center Methods for treating brain insulin resistance
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2017112897A1 (en) * 2015-12-22 2017-06-29 Engineered Controls International, Llc Noise reducing filler valve
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
KR20240051304A (ko) * 2018-07-23 2024-04-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201636362A (zh) * 2015-01-09 2016-10-16 美國禮來大藥廠 Ｇｉｐ及ｇｌｐ－１共促效劑化合物

Also Published As

Publication number Publication date
PH12021550154A1 (en) 2021-09-13
CN119504975A (zh) 2025-02-25
JOP20250198A1 (ar) 2025-08-03
WO2020023386A1 (en) 2020-01-30
JOP20210016A1 (ar) 2021-01-21
US20200024322A1 (en) 2020-01-23
MA53382A (fr) 2021-06-02
US20250051415A1 (en) 2025-02-13
US11084861B2 (en) 2021-08-10
SA521421080B1 (ar) 2024-11-04
MY197569A (en) 2023-06-25
ZA202105821B (en) 2025-07-30
EP4549454A2 (en) 2025-05-07
CA3107345A1 (en) 2020-01-30
MX2021000793A (es) 2021-04-12
CA3178366C (en) 2026-02-24
CR20210040A (es) 2021-02-12
CL2021000158A1 (es) 2021-07-30
US12252524B2 (en) 2025-03-18
KR20210031533A (ko) 2021-03-19
EP4549454A3 (en) 2025-07-09
CN112469731B (zh) 2024-11-29
JP2023171775A (ja) 2023-12-05
JP2021508731A (ja) 2021-03-11
JP7626530B2 (ja) 2025-02-07
ZA202100235B (en) 2025-03-26
CA3294907A1 (en) 2026-03-02
CA3178366A1 (en) 2020-01-30
CN112469731A (zh) 2021-03-09
SG11202100128UA (en) 2021-02-25
DOP2021000016A (es) 2021-03-15
AU2019311000A1 (en) 2021-02-25
UA129537C2 (uk) 2025-05-28
TW202523681A (zh) 2025-06-16
ECSP21004913A (es) 2021-02-26
IL279827A (en) 2021-03-01
EP3827015B1 (en) 2026-02-18
JP2021183614A (ja) 2021-12-02
TWI735917B (zh) 2021-08-11
AU2023202709A1 (en) 2023-05-18
TW202332688A (zh) 2023-08-16
AU2019311000B2 (en) 2023-02-02
CO2021000453A2 (es) 2021-01-29
CA3107345C (en) 2025-07-08
TW202019952A (zh) 2020-06-01
PE20260005A1 (es) 2026-01-06
JP6920559B2 (ja) 2021-08-18
EP3827015A1 (en) 2021-06-02
ZA202106369B (en) 2025-01-29
KR20240051304A (ko) 2024-04-19
US20220048967A1 (en) 2022-02-17
KR20210016632A (ko) 2021-02-16
BR112020026671A2 (pt) 2021-04-06
TW202140527A (zh) 2021-11-01
PE20211637A1 (es) 2021-08-24
KR102351313B1 (ko) 2022-01-17
US20250122259A9 (en) 2025-04-17
TWI810606B (zh) 2023-08-01
FI3827015T3 (fi) 2026-04-30

Similar Documents

Publication Publication Date Title
TWI863239B (zh) Gip/glp1共促效劑化合物
AU2022231763B2 (en) Protein tyrosine-tyrosine analogs and methods of using the same
TWI770781B (zh) Gip/glp1共促效劑化合物
TWI917014B (zh) Gip/glp1共促效劑化合物
EA048422B1 (ru) Соединения-коагонисты gip/glp1
EA052413B1 (ru) Соединения-коагонисты gip/glp-1
BR122025020472A2 (pt) Compostos coagonistas de gip/glp1, composição farmacêutica e uso dos mesmos
HK40046538B (en) Gip/glp1 co-agonist compounds
HK40046538A (en) Gip/glp1 co-agonist compounds